创新药概念午后再度拉升，创新药ETF天弘（517380）涨超1.3%，机构：6月下旬以来板块的调整已基本到位

Group 1 - The core viewpoint of the articles highlights a positive outlook for the innovative drug sector, driven by recent government measures to support high-quality development in this field [1][2] - The National Healthcare Security Administration and the National Health Commission have issued measures that include 16 initiatives to support the entire chain of innovative drug development, approval, hospital use, and multi-payment systems [1] - Recent market performance shows significant gains for companies like Kexing Pharmaceutical and Rongchang Bio, with Kexing rising over 18% and Rongchang over 11% [1] Group 2 - The Tianhong Innovative Drug ETF (517380) has seen a net inflow of over 36 million yuan from June 25 to June 30, indicating strong investor interest [1] - The Tianhong Innovative Drug ETF is the largest in the market, covering both A-shares and Hong Kong stocks, and tracks the Hang Seng Shanghai-Hong Kong Innovative Drug Selected 50 Index [2] - Analysts from Huayuan Securities and Zhongtai Securities express confidence in the innovative drug sector, suggesting that the recent adjustments have reached a bottom and that the sector is expected to continue rising, particularly for companies with strong catalysts [1][2]